CN113166110A - 2-氨基嘧啶类化合物及其应用 - Google Patents

2-氨基嘧啶类化合物及其应用 Download PDF

Info

Publication number
CN113166110A
CN113166110A CN201980077663.4A CN201980077663A CN113166110A CN 113166110 A CN113166110 A CN 113166110A CN 201980077663 A CN201980077663 A CN 201980077663A CN 113166110 A CN113166110 A CN 113166110A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
alkyl
halogen
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980077663.4A
Other languages
English (en)
Other versions
CN113166110B (zh
Inventor
丁克
丁健
陆小云
耿美玉
李姗
谢华
陈灏
童林江
任小梅
冯芳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Jinan University
Original Assignee
Shanghai Institute of Materia Medica of CAS
Jinan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Jinan University filed Critical Shanghai Institute of Materia Medica of CAS
Publication of CN113166110A publication Critical patent/CN113166110A/zh
Application granted granted Critical
Publication of CN113166110B publication Critical patent/CN113166110B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种2‑氨基嘧啶类化合物及其应用。该2‑氨基嘧啶类化合物的结构如I所示，该类化合物可以有效抑制EGFR蛋白激酶耐药突变体(如EGFRT790M和EGFRT790M/C797S)的活性，并可以克服现有第三代选择性EGFRT790M小分子抑制剂Osimertinib(AZD9291)，Olmutinib(HM6171)，Rociletinib(CO‑1686)等诱发的非小细胞肺癌等肿瘤病人的临床耐药。

Description

PCT国内申请，说明书已公开。

Claims (24)

  1. PCT国内申请，权利要求书已公开。
CN201980077663.4A 2018-12-12 2019-12-11 2-氨基嘧啶类化合物及其应用 Active CN113166110B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811517594 2018-12-12
CN2018115175948 2018-12-12
PCT/CN2019/124686 WO2020119739A1 (zh) 2018-12-12 2019-12-11 2-氨基嘧啶类化合物及其应用

Publications (2)

Publication Number Publication Date
CN113166110A true CN113166110A (zh) 2021-07-23
CN113166110B CN113166110B (zh) 2023-08-11

Family

ID=71076798

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980077663.4A Active CN113166110B (zh) 2018-12-12 2019-12-11 2-氨基嘧啶类化合物及其应用

Country Status (2)

Country Link
CN (1) CN113166110B (zh)
WO (1) WO2020119739A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292378A (zh) * 2019-05-22 2021-01-29 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用
WO2023068858A1 (en) * 2021-10-20 2023-04-27 Hanmi Pharm. Co., Ltd. Therapeutically effective combination of a flt3 inhibitor and a bcl-2 inhibitor for the treatment of acute myeloid leukemia
WO2024087419A1 (zh) * 2022-10-28 2024-05-02 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112334451A (zh) 2018-02-15 2021-02-05 诺维逊生物股份有限公司 作为激酶抑制剂的杂环化合物
CN113264920B (zh) * 2021-05-10 2022-09-02 中国药科大学 一种嘧啶苯并六元环母核的cdk6抑制剂及其制备方法和应用

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183900A1 (en) * 2004-10-29 2006-08-17 Shenlin Huang Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US20100105655A1 (en) * 2008-10-29 2010-04-29 Astrazeneca Ab Novel compounds 515
CN101723936A (zh) * 2008-10-27 2010-06-09 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
US20100267707A1 (en) * 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
US20170121326A1 (en) * 2015-10-28 2017-05-04 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
WO2017200016A1 (ja) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
CN107382974A (zh) * 2017-06-08 2017-11-24 扬州市三药制药有限公司 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用
WO2019190259A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183900A1 (en) * 2004-10-29 2006-08-17 Shenlin Huang Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
US20100267707A1 (en) * 2006-06-22 2010-10-21 Merck Sharp & Dohme Corp. Tyrosine Kinase Inhibitors
CN101723936A (zh) * 2008-10-27 2010-06-09 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
US20100105655A1 (en) * 2008-10-29 2010-04-29 Astrazeneca Ab Novel compounds 515
CN105085489A (zh) * 2014-11-05 2015-11-25 上海页岩科技有限公司 嘧啶或吡啶类化合物、其制备方法和医药用途
US20170121326A1 (en) * 2015-10-28 2017-05-04 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
WO2017200016A1 (ja) * 2016-05-17 2017-11-23 公益財団法人がん研究会 Ｅｇｆｒ－ｔｋｉ耐性を獲得した肺癌の治療薬
CN107382974A (zh) * 2017-06-08 2017-11-24 扬州市三药制药有限公司 一种嘧啶胺类化合物作为周期蛋白依赖性激酶4/6抑制剂的应用
WO2019190259A1 (ko) * 2018-03-30 2019-10-03 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACS: "RN1335498-99-1", 《STN》 *
R.B.西尔弗曼编，郭宗儒主译: "《有机药物化学》", 31 January 2008, 化学工业出版社 生物•医药出版分社 *
平丽红等编: "《实用治疗药物学》", 31 March 2018 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112292378A (zh) * 2019-05-22 2021-01-29 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用
CN112292378B (zh) * 2019-05-22 2024-02-06 上海翰森生物医药科技有限公司 含吲哚类衍生物抑制剂、其制备方法和应用
WO2023068858A1 (en) * 2021-10-20 2023-04-27 Hanmi Pharm. Co., Ltd. Therapeutically effective combination of a flt3 inhibitor and a bcl-2 inhibitor for the treatment of acute myeloid leukemia
WO2024087419A1 (zh) * 2022-10-28 2024-05-02 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用

Also Published As

Publication number Publication date
CN113166110B (zh) 2023-08-11
WO2020119739A1 (zh) 2020-06-18

Similar Documents

Publication Publication Date Title
CN105601573B (zh) 2-氨基嘧啶类化合物及其药物组合物和应用
CN113166110B (zh) 2-氨基嘧啶类化合物及其应用
US10329274B2 (en) Indole carboxamide compounds
JP5756518B2 (ja) 複素環アルキニルベンゼン化合物と、その医療用組成物および使用
JP6945015B2 (ja) Ｎ２，ｎ４−ジフェニルピリミジン−２，４−ジアミン誘導体、その製造方法、およびこれを有効成分として含む癌の予防または治療用の薬学的組成物
TWI535442B (zh) A nitrogen-containing heterocyclic compound having an action of inhibiting the production of canine erythritine
TW201734013A (zh) Egfr酪胺酸激酶之臨床重要突變體之選擇性抑制劑
JP2020506922A5 (zh)
CN103012399B (zh) 7-氧代吡啶并嘧啶类化合物及其药用组合物和应用
CN111606904B (zh) 氮杂吲哚类化合物及其应用
CN110305161A (zh) 2-氨基嘧啶类化合物及其应用
US20240116921A1 (en) Lactam (hetero)arylfusedpyrimidine derivatives as inhibitors of erbb2
ES2863925T3 (es) Derivados de 3-(pirimidinamina 4,5-sustituida)fenilo deuterados y aplicaciones de los mismos
CN111356687B (zh) 含嘧啶的三取代咪唑类化合物及其应用
CN112538038B (zh) 2-吲哚酮类ERRα反向激动剂及其药物组合物和应用
CN114072387A (zh) 吲唑类化合物及其药用组合物和应用
CN112759589B (zh) 嘧啶并吡啶酮类化合物及其应用
CN112313213B (zh) 3-氨基吡唑类化合物及其应用
CN114539263A (zh) 一类含氮并杂环化合物及其药用组合物和应用
JP2023546352A (ja) Ｂｃｒ－ａｂｌチロシンキナーゼの阻害のための５－及び６－アザインドール化合物
JP2021533143A (ja) Ｃｄｋ８／１９阻害薬
WO2020192302A1 (zh) 含嘧啶的三取代咪唑类化合物及其应用
CN103570731A (zh) 嘧啶并三环或嘧啶并四环类化合物及其药用组合物和应用
WO2023246903A1 (zh) 含硒杂环类化合物及其药用组合物和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant